Alzheimer Disease  >>  elenbecestat (E2609)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elenbecestat (E2609) / Eisai, Biogen
NCT01294540: Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort

Completed
1
73
US
Drug: E2609, Placebo
Eisai Inc.
Alzheimer's Disease
10/11
12/11
NCT01716897: An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

Completed
1
18
US
E2609
Eisai Inc.
Alzheimer's Disease
12/12
02/13
NCT01600859: Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

Checkmark For mild cognitive impairment or mild dementia due to Alzheimer's disease
Nov 2013 - Nov 2013: For mild cognitive impairment or mild dementia due to Alzheimer's disease
Completed
1
65
US
E2609, Placebo for E2609
Eisai Inc.
Alzheimer's Disease
09/13
10/13
NCT02859207: A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Completed
1
32
US
E2609
Eisai Inc.
Early Alzheimer's Disease
12/16
01/17

Download Options